Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Generics: what's in a name?

Keith LG, Oleszczuk JJ, Stika CS, Stine S.

Int J Fertil Womens Med. 1998 May-Jun;43(3):139-49. Review.

PMID:
9692536
2.

Current approaches to the use of generic antiepileptic drugs.

Krämer G, Biraben A, Carreno M, Guekht A, de Haan GJ, Jedrzejczak J, Josephs D, van Rijckevorsel K, Zaccara G.

Epilepsy Behav. 2007 Aug;11(1):46-52. Epub 2007 May 29. Review.

PMID:
17537678
3.

[Generic drugs in the treatment of epilepsy].

González de Dios J, Ochoa-Sangrador C, Sempere AP.

Rev Neurol. 2005 Dec 1-15;41(11):676-83. Review. Spanish.

4.

Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.

Bialer M, Midha KK.

Epilepsia. 2010 Jun;51(6):941-50. doi: 10.1111/j.1528-1167.2010.02573.x. Epub 2010 Apr 8. Review.

5.

[Generics: essentially similar, bioequivalent but not identical].

Even-Adin D, De Muylder JA, Sternon J.

Rev Med Brux. 2001 Dec;22(6):513-20. Review. French.

PMID:
11811047
6.

Bioequivalence and generic prescribing: an industrial view.

Pidgen A.

J Pharm Pharmacol. 1996 Jan;48(1):11-6. Review.

PMID:
8722487
7.

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction.

Coma A, Zara C, Godman B, Agustí A, Diogène E, Wettermark B, Haycox A.

Expert Rev Pharmacoecon Outcomes Res. 2009 Dec;9(6):569-81. doi: 10.1586/erp.09.58. Review.

PMID:
19941434
8.

Bioequivalence and generic prescribing: a pharmacy view.

Calvert RT.

J Pharm Pharmacol. 1996 Jan;48(1):9-10. Review. No abstract available.

PMID:
8722486
9.

Prescribing generic antiepileptic drugs: Issues and concerns for nurse practitioners.

Barrett MW.

J Am Acad Nurse Pract. 2010 Jun;22(6):300-4. doi: 10.1111/j.1745-7599.2010.00511.x. Review.

PMID:
20536627
10.
11.

Biosimilars in clinical practice.

Mikhail A.

Kidney Blood Press Res. 2007;30 Suppl 1:18-22. Epub 2007 Aug 27. Review. No abstract available.

12.

Drug substitution in transplantation: a National Kidney Foundation White Paper.

Sabatini S, Ferguson RM, Helderman JH, Hull AR, Kirkpatrick BS, Barr WH.

Am J Kidney Dis. 1999 Feb;33(2):389-97. Review.

PMID:
10023656
13.

Think INN, prescribe INN, dispense INN: good professional practice.

[No authors listed]

Prescrire Int. 2000 Dec;9(50):184-90. Review.

PMID:
11475502
14.

Generic prescribing in epilepsy.

[No authors listed]

Drug Ther Bull. 2009 Dec;47(12):141-4. doi: 10.1136/dtb.2009.11.0051. Review.

PMID:
20009042
15.

[Regulatory framework for prescription and recommendations for proper use].

Bouvenot G, Villani P.

Rev Prat. 2013 Oct;63(8):1165-70. Review. French. No abstract available.

PMID:
24298839
16.

Current regulatory approaches of bioequivalence testing.

Karalis V, Macheras P.

Expert Opin Drug Metab Toxicol. 2012 Aug;8(8):929-42. doi: 10.1517/17425255.2012.690394. Epub 2012 Jun 11. Review.

PMID:
22681436
17.

Medical and psychiatric implications of generic drugs.

Diamond BI, Albrecht JW.

Psychopathology. 1987;20 Suppl 1:92-8. Review.

PMID:
3321135
18.

Generics: keep a balanced view.

[No authors listed]

Prescrire Int. 2014 Feb;23(146):52-5. Review.

PMID:
24669392
19.

Generic versus branded pharmacotherapy in Parkinson's disease: does it matter? A review.

Go CL, Rosales RL, Schmidt P, Lyons KE, Pahwa R, Okun MS.

Parkinsonism Relat Disord. 2011 Jun;17(5):308-12. doi: 10.1016/j.parkreldis.2011.02.005. Epub 2011 Mar 1. Review.

PMID:
21367644
20.

Bioequivalence testing of immunosuppressants: concepts and misconceptions.

Christians U, Klawitter J, Clavijo CF.

Kidney Int Suppl. 2010 Mar;(115):S1-7. doi: 10.1038/ki.2009.504. Review.

PMID:
20150904

Supplemental Content

Support Center